Lateral flow testing should not be used as a green light for activities

Two studies demonstrate new PCI approaches offer benefits to patients and physicians
29 April 2021
Pharmacist-led smartphone app benefits kidney transplant recipients
29 April 2021

Lateral flow testing should not be used as a green light for activities

The United Kingdom government plans to implement mass scale population testing for SARS-CoV-2 infection using Lateral Flow Devices (LFDs), yet the devices’ sensitivity is unknown. A study published in the open access journal PLOS Biology by Alan McNally at University of Birmingham, UK, and colleagues suggests while LFDs are highly effective in identifying SARS-CoV-2 in individuals with high quantities of viral RNA present on the test swab, they are inaccurate at diagnosing infections in individuals with lower viral loads.

Comments are closed.